Zusammenfassung
Die Diagnose und Therapie von Gallengangskarzinomen sind eine interdisziplinäre Herausforderung. Im diagnostischen und therapeutischen Vorgehen ist zwischen intrahepatischen und extrahepatischen Tumoren zu unterscheiden. Neben der Sonografie haben die endoskopisch retrograde Cholangiografie und Schnittbildverfahren eine zentrale Stellung in der Diagnosesicherung und Therapieplanung. Die einzige kurative Therapie ist die radikale Resektion. Da bei Diagnosestellung bereits viele Tumoren im fortgeschrittenen Stadium sind, kann nur der kleinere Teil der Patienten in kurativer Intention reseziert werden. Die Gefäßinfiltration der Pfortader stellt keine generelle Kontraindikation zur Operation mehr dar. Während eine Lebertransplantation beim intrahepatischen Cholangiokarzinom nicht sinnvoll ist, deuten neueste Daten auf einen möglichen Vorteil der Transplantation bei Klatskin-Tumoren hin. Ein wesentliches Ziel der palliativen Therapie ist die Prophylaxe und Behandlung der obstruktiven Cholangitis. Die Cholangitis ist die Haupttodesursache insbesondere des perihilären Klatskin-Tumors, der häufigsten Manifestation des CC. Ist eine Resektion nicht möglich, können lokal ablative Verfahren zum Einsatz kommen. Dabei ist die photodynamische Therapie das bisher am besten untersuchte Verfahren. Prospektiv kontrollierte Studien zeigten eine Verlängerung des Überlebens. Der Stellenwert radiologisch-interventioneller Verfahren sowie der perkutanen Radio- und Radiochemotherapie ist noch nicht ausreichend durch Studien belegt. Auch die Effizienz systemischer Chemotherapien ist unklar, da bis heute prospektiv evaluierte Chemotherapieregime weitgehend fehlen. Allerdings gibt es Hinweise für einen Vorteil einer Gemcitabin-basierten Chemotherapie. Um Patienten der bestmöglichen Therapie zuzuführen, ist eine enge interdisziplinäre Zusammenarbeit notwendig, und um Fortschritte bei der Therapie des Cholangiokarzinoms zu erzielen, ist die Testung neuer Ansätze in klinischen Studien unbedingt notwendig.
Abstract
The diagnosis of and therapy for cholangiocarcinomas still remains an interdisciplinary challenge. For diagnostic and therapeutic purposes intra- and extrahepatic cholangiocarcinomas need to be distinguished. Multiple imaging tools such as sonography, multidetector computer tomography, magnetic resonance tomography as well as endoscopic ultrasound and endoscopic retrograde cholangiography for the diagnosis and localisation of these tumours are available. To date, surgical resection is the only curative treatment. At the time of diagnosis, most of the tumours are advanced. Therefore, only a small percentage of patients are suitable for curative surgery. Infiltration of the portal vein no longer constitutes a contraindication for surgery. Liver transplantation is not a reasonable option for intrahepatic cholangiocarcinomas but may be of advantage for perihilar Klatskin tumours. Severe cholangitis is the main cause of death of patients with obstructive cholangiocarcinomas. Drainage of the biliary tree system or surgery with construction of a biliary-digestive anastomosis is often necessary. If possible, a photodynamic therapy (PDT) should be performed in addition to biliary drainage. PDT has been shown to facilitate biliary drainage and to improve survival. The value of radiologist-assisted interventional procedures as well as percutaneous ablation and radiochemotherapy is not well established. In addition, so far, there is no standardised chemotherapy in a palliative situation established but there is some evidence for a benefit of gemcitabine-based chemotherapy. For the best care and treatment of patients with cholangiocarcinomas an interdisciplinary approach is required and to achieve progress in the therapy patients should be included in prospective clinical trials to test new approaches.
Schlüsselwörter
cholangiozelluläres Karzinom - Klatskin-Tumor - Gallengangskarzinom
Key words
cholangiocellular carcinoma - Klatskin tumours - bile duct cancer
Literatur
1
Bismuth H, Nakache R, Diamond T.
Management strategies in resection for hilar cholangiocarcinoma.
Ann Surg.
1992;
215
31-38
2
Pitt H A, Dooley W C, Yeo C J. et al .
Malignancies of the biliary tree.
Curr Probl Surg.
1995;
32
1-90
3
Bergquist A, Ekbom A, Olsson R. et al .
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.
J Hepatol.
2002;
36
321-327
4
Brandsaeter B, Isoniemi H, Broome U. et al .
Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy.
J Hepatol.
2004;
40
815-822
5
Callea F, Sergi C, Fabbretti G. et al .
Precancerous lesions of the biliary tree.
J Surg Oncol Suppl.
1993;
131-133
6
Lipsett P A, Pitt H A, Colombani P M. et al .
Choledochal cyst disease. A changing pattern of presentation.
Ann Surg.
1994;
220
644-652
7
Watanapa P.
Cholangiocarcinoma in patients with opisthorchiasis.
Br J Surg.
1996;
83
1062-1064
8
Watanapa P, Watanapa W B.
Liver fluke-associated cholangiocarcinoma.
Br J Surg.
2002;
89
962-970
9
Kobayashi M, Ikeda K, Saitoh S. et al .
Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis.
Cancer.
2000;
88
2471-2477
10
Bergquist A, Glaumann H, Persson B. et al .
Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.
Hepatology.
1998;
27
311-316
11
Nakeeb A, Pitt H A, Sohn T A. et al .
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.
Ann Surg.
1996;
224
463-473; discussion 473 - 465
12
Kurzawinski T R, Deery A, Dooley J S. et al .
A prospective study of biliary cytology in 100 patients with bile duct strictures.
Hepatology.
1993;
18
1399-1403
13
Glasbrenner B, Ardan M, Boeck W. et al .
Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography.
Endoscopy.
1999;
31
712-717
14
Schoefl R, Haefner M, Wrba F. et al .
Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses.
Scand J Gastroenterol.
1997;
32
363-368
15
Pugliese V, Conio M, Nicolo G. et al .
Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study.
Gastrointest Endosc.
1995;
42
520-526
16
Fogel E L, Sherman S.
How to improve the accuracy of diagnosis of malignant biliary strictures.
Endoscopy.
1999;
31
758-760
17
Foutch P G.
Diagnosis of cancer by cytologic methods performed during ERCP.
Gastrointest Endosc.
1994;
40
249-252
18
Howell D A, Beveridge R P, Bosco J. et al .
Endoscopic needle aspiration biopsy at ERCP in the diagnosis of biliary strictures.
Gastrointest Endosc.
1992;
38
531-535
19
Farrell R J, Jain A K, Brandwein S L. et al .
The combination of stricture dilation, endoscopic needle aspiration, and biliary brushings significantly improves diagnostic yield from malignant bile duct strictures.
Gastrointest Endosc.
2001;
54
587-594
20
Mohandas K M, Swaroop V S, Gullar S U. et al .
Diagnosis of malignant obstructive jaundice by bile cytology: results improved by dilating the bile duct strictures.
Gastrointest Endosc.
1994;
40
150-154
21
Stewart C J, Burke G M.
Value of p53 immunostaining in pancreatico-biliary brush cytology specimens.
Diagn Cytopathol.
2000;
23
308-313
22
Morales C P, Burdick J S, Saboorian M H. et al .
In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies.
Gastrointest Endosc.
1998;
48
402-405
23
Itoi T, Shinohara Y, Takeda K. et al .
Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers.
Gastrointest Endosc.
2000;
52
380-386
24
Menzel J, Domschke W.
Intraductal ultrasonography (IDUS) of the pancreato-biliary duct system. Personal experience and review of literature.
Eur J Ultrasound.
1999;
10
105-115
25
Tamada K, Ido K, Ueno N. et al .
Preoperative staging of extrahepatic bile duct cancer with intraductal ultrasonography.
Am J Gastroenterol.
1995;
90
239-246
26
Zech C J, Schoenberg S O, Reiser M. et al .
Cross-sectional imaging of biliary tumors: current clinical status and future developments.
Eur Radiol.
2004;
14
1174-1187
27
Nesbit G M, Johnson C D, James E M. et al .
Cholangiocarcinoma: diagnosis and evaluation of resectability by CT and sonography as procedures complementary to cholangiography.
Am J Roentgenol.
1988;
151
933-938
28
Rosch T, Meining A, Fruhmorgen S. et al .
A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures.
Gastrointest Endosc.
2002;
55
870-876
29
Tillich M, Mischinger H J, Preisegger K H. et al .
Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma.
Am J Roentgenol.
1998;
171
651-658
30
Zech C J, Herrmann K A, Huber A. et al .
High-resolution MR-imaging of the liver with T 2-weighted sequences using integrated parallel imaging: comparison of prospective motion correction and respiratory triggering.
J Magn Reson Imaging.
2004;
20
443-450
31
Zech C J, Schoenberg S O, Herrmann K A. et al .
Modern visualization of the liver with MRT. Current trends and future perspectives.
Radiologe.
2004;
44
1160-1169
32
Lee S S, Kim M H, Lee S K. et al .
MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma.
Gastrointest Endosc.
2002;
56
25-32
33
Lopera J E, Soto J A, Munera F.
Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions.
Radiology.
2001;
220
90-96
34
Kluge R, Schmidt F, Caca K. et al .
Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.
Hepatology.
2001;
33
1029-1035
35
Jadvar H, Henderson R W, Conti P S.
[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
J Comput Assist Tomogr.
2007;
31
223-228
36
Grobmyer S R, Wang L, Gonen M. et al .
Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy.
Ann Surg.
2006;
244
260-264
37
Nakagawa T, Kamiyama T, Kurauchi N. et al .
Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma.
World J Surg.
2005;
29
728-733
38
Hanazaki K, Kajikawa S, Shimozawa N. et al .
Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis.
Hepatogastroenterology.
2002;
49
311-316
39
Huang J L, Biehl T R, Lee F T. et al .
Outcomes after resection of cholangiocellular carcinoma.
Am J Surg.
2004;
187
612-617
40
Shimoda M, Farmer D G, Colquhoun S D. et al .
Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.
Liver Transpl.
2001;
7
1023-1033
41
Weber S M, Jarnagin W R, Klimstra D. et al .
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes.
J Am Coll Surg.
2001;
193
384-391
42
Chu K M, Fan S T.
Intrahepatic cholangiocarcinoma in Hong Kong.
J Hepatobiliary Pancreat Surg.
1999;
6
149-153
43
Lang H, Kaiser G M, Zopf T. et al .
Surgical therapy of hilar cholangiocarcinoma.
Chirurg.
2006;
77
325-334
44
Nagino M, Kamiya J, Nishio H. et al .
Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up.
Ann Surg.
2006;
243
364-372
45
Witzigmann H, Berr F, Ringel U. et al .
Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1 /r2 resection.
Ann Surg.
2006;
244
230-239
46
Ghali P, Marotta P J, Yoshida E M. et al .
Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience.
Liver Transpl.
2005;
11
1412-1416
47
Heimbach J K, Haddock M G, Alberts S R. et al .
Transplantation for hilar cholangiocarcinoma.
Liver Transpl.
2004;
10
S65-68
48
Casavilla F A, Marsh J W, Iwatsuki S. et al .
Hepatic resection and transplantation for peripheral cholangiocarcinoma.
J Am Coll Surg.
1997;
185
429-436
49
Sotiropoulos G C, Lang H, Broelsch C E.
Surgical management of recurrent intrahepatic cholangiocellular carcinoma after liver resection.
Surgery.
2005;
137
669-670
50
Freeman M L, Overby C.
Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents.
Gastrointest Endosc.
2003;
58
41-49
51
Hintze R E, Abou-Rebyeh H, Adler A. et al .
Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors.
Gastrointest Endosc.
2001;
53
40-46
52
De Palma G D, Pezzullo A, Rega M. et al .
Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study.
Gastrointest Endosc.
2003;
58
50-53
53
Levy M J, Baron T H, Gostout C J. et al .
Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach.
Clin Gastroenterol Hepatol.
2004;
2
273-285
54
Isayama H, Komatsu Y, Tsujino T. et al .
A prospective randomised study of „covered” versus „uncovered” diamond stents for the management of distal malignant biliary obstruction.
Gut.
2004;
53
729-734
55
Sohn T A, Yeo C J, Cameron J L. et al .
Do preoperative biliary stents increase postpancreaticoduodenectomy complications?.
J Gastrointest Surg.
2000;
4
258-267; discussion 267 - 258
56
Wong Kee Song L M, Wang K K, Zinsmeister A R.
Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Cancer.
1998;
82
421-427
57
Pahernik S A, Dellian M, Berr F. et al .
Distribution and pharmacokinetics of Photofrin in human bile duct cancer.
J Photochem Photobiol B.
1998;
47
58-62
58
Ortner M E, Caca K, Berr F. et al .
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.
Gastroenterology.
2003;
125
1355-1363
59
Wiedmann M, Berr F, Schiefke I. et al .
Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study.
Gastrointest Endosc.
2004;
60
68-75
60
Schaffer M, Schaffer P M, Corti L. et al .
Photofrin II as an efficient radiosensitizing agent in an experimental tumor.
Onkologie.
2001;
24
482-485
61
Gobien R P, Stanley J H, Soucek C D. et al .
Routine preoperative biliary drainage: effect on management of obstructive jaundice.
Radiology.
1984;
152
353-356
62
Burger I, Hong K, Schulick R. et al .
Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution.
J Vasc Interv Radiol.
2005;
16
353-361
63
Vogl T J, Schwarz W, Eichler K. et al .
Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
J Cancer Res Clin Oncol.
2006;
132
745-755
64
Salem R, Thurston K G, Carr B I. et al .
Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.
J Vasc Interv Radiol.
2002;
13
S223-229
65
Carr B I.
Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.
Liver Transpl.
2004;
10
S107-110
66
Slakey D P.
Radiofrequency ablation of recurrent cholangiocarcinoma.
Am Surg.
2002;
68
395-397
67
Zgodzinski W, Espat N J.
Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma.
World J Gastroenterol.
2005;
11
5239-5240
68
Kubicka S.
Cholangiocellular and gallbladder carcinoma.
Z Gastroenterol.
2004;
42
397-402
69
Wiedmann M, Schoppmeyer K, Witzigmann H. et al .
Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder.
Z Gastroenterol.
2005;
43
305-315
70
Glimelius B, Hoffman K, Sjoden P O. et al .
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
Ann Oncol.
1996;
7
593-600
71
Thongprasert S.
The role of chemotherapy in cholangiocarcinoma.
Ann Oncol.
2005;
16 (Suppl 2)
ii93-96
72
Patt Y Z, Hassan M M, Aguayo A. et al .
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Cancer.
2004;
101
578-586
73
Okusaka T, Ishii H, Funakoshi A. et al .
Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer.
Cancer Chemother Pharmacol.
2006;
57
647-653
74
Andre T, Tournigand C, Rosmorduc O. et al .
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
Ann Oncol.
2004;
15
1339-1343
75
Knox J J, Hedley D, Oza A. et al .
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
J Clin Oncol.
2005;
23
2332-2338
76
Ducreux M, Van Cutsem E, Van Laethem J L. et al .
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40 955 EORTC trial.
Eur J Cancer.
2005;
41
398-403
77
Rao S, Cunningham D, Hawkins R E. et al .
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
Br J Cancer.
2005;
92
1650-1654
78
Pazdur R, Royce M E, Rodriguez G I. et al .
Phase II trial of docetaxel for cholangiocarcinoma.
Am J Clin Oncol.
1999;
22
78-81
79
Jones D V Jr, Lozano R, Hoque A. et al .
Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas.
J Clin Oncol.
1996;
14
2306-2310
80
Boeck S, Hinke A, Wilkowski R. et al .
Importance of performance status for treatment outcome in advanced pancreatic cancer.
World J Gastroenterol.
2007;
13
224-227
81
Philip P A, Mahoney M R, Allmer C. et al .
Phase II study of erlotinib in patients with advanced biliary cancer.
J Clin Oncol.
2006;
24
3069-3074
82
Pitt H A, Nakeeb A, Abrams R A. et al .
Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.
Ann Surg.
1995;
221
788-797; discussion 797 - 788
83
Todoroki T, Takahashi H, Koike N. et al .
Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival.
Hepatogastroenterology.
1999;
46
2114-2121
84
Todoroki T, Ohara K, Kawamoto T. et al .
Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma.
Int J Radiat Oncol Biol Phys.
2000;
46
581-587
85
Morganti A G, Trodella L, Valentini V. et al .
Combined modality treatment in unresectable extrahepatic biliary carcinoma.
Int J Radiat Oncol Biol Phys.
2000;
46
913-919
86
Whittington R, Neuberg D, Tester W J. et al .
Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.
J Clin Oncol.
1995;
13
227-232
PD Dr. Prof. Claus Schäfer
Medizinische Klinik und Poliklinik II, Klinikum der Universität München - Campus Großhadern
Marchioninistraße 15
81377 München
Phone: ++ 49/89/70 95 31 30
Fax: ++ 49/89/70 95 61 83
Email: claus.schaefer@med.uni-muenchen.de